New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
10:51 EDTEW, MDTEdwards up after court limits sale of Medtronic's CoreValve in U.S.
Shares of cardiovascular technology company Edwards Lifesciences (EW) are rising today after a U.S. district court granted a preliminary injunction limiting the sale of Medtronic's (MDT) CoreValve system in the U.S. Shares of Medtronic, meanwhile, are falling following the news. WHAT'S NEW: On April 12, Edwards said a U.S. district court in Delaware granted a preliminary injunction, to go into effect in seven days, limiting the sale of Medtronic's CoreValue system in the U.S. In addition, the court ordered Medtronic and Edwards to enter into immediate talks to agree on a mechanism that will enable physicians at facilities currently trained on CoreValve to make a clinical judgment as to which device to implant, free from the limitations of the injunction. Medtronic responded on April 13 by saying that the ruling has no impact on the sale or marketing of CoreValue outside of the U.S. or the use of CoreValue in the current U.S. clinical trials. Medtronic is appealing the court's injunction and intends to ask the Federal Circuit Court of Appeals to prevent it from going into effect until it determines if the injunction was properly issued. ANALYST REACTION: JPMorgan upgraded Edwards Lifesciences to Neutral from Underweight following the news and raised its price target for shares to $78 from $60. JPMorgan also downgraded Medtronic to Neutral and lowered its price target on that stock to $64 from $69. Another firm, CRT Capital, also upgraded Edwards Lifesciences in response to the news. CRT Capital analyst Shagun Chadha feels that the court decision to grant a preliminary injunction against MDT’s CoreValve focuses the market balance in favor of Edwards and took the stock up to Buy from Fair Value with a price target of $87. Canaccord Genuity analyst Jason Mills said that Edwards achieved a "surprising" and noteworthy win in the courts. Mills noted, however, that he still foresees Edwards to cash in via other forms of equitable relief in lieu of a final injunction. The firm is maintaining its 12-month price target of $84 on Edwards Lifesciences shares. PRICE ACTION: During morning trading, shares of Edwards Lifesciences were up $10.01 or 13.72% to $82.98. Shares of Medtronic fell $1.28 or 2.16% to $57.92.
News For EW;MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
08:42 EDTMDTMedtronic coverage resumed with a Buy at Goldman
Subscribe for More Information
January 26, 2015
17:06 EDTMDTMedtronic completes acquisition of Covidien for $49.9B
Subscribe for More Information
08:34 EDTEWEdwards Lifesciences should be bought on strong TAVR data, says Wells Fargo
Wells Fargo commends buying shares of Edwards Lifesciences after the firm viewed the most recent Transcatheter Valve Therapies registry update and estimated that the TAVR market may have grown 20% sequentially last quarter, versus its previous estimate of 1% sequential growth. The firm keeps an Outperform rating on Edwards.
07:17 EDTMDT, EWSociety of Thoracic Surgeons to hold annual meeting
51st Annual Meeting of STS is being held in San Diego, California on January 24-28.
07:08 EDTMDTMedtronic pending acquisition of Covidien approved by Irish High Court
Subscribe for More Information
January 23, 2015
16:33 EDTMDTMedtronic reports 5.1% passive stake in Intersect ENT
Subscribe for More Information
15:46 EDTMDTPiper Jaffray's medtech analysts hold an analyst/industry conference call
Subscribe for More Information
08:36 EDTMDTMedtronic receives FDA approval for for the Medtronic Enterra II System
Subscribe for More Information
January 21, 2015
18:06 EDTMDTS&P announces changes to the S&P 500, MidCap 400, SmallCap 600 indices
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use